BioXcel Therapeutics
BTAI
BTAI
73 hedge funds and large institutions have $28.2M invested in BioXcel Therapeutics in 2023 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 23 increasing their positions, 27 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
73
Holders Change
-12
Holders Change %
-14.12%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
23
Reduced
27
Closed
24
Calls
$776K
Puts
$1.52M
Net Calls
-$739K
Net Calls Change
-$994K
Top Buyers
| 1 |
1
Adage Capital Partners
Boston,
Massachusetts
|
$1.37M |
| 2 |
2
Morgan Stanley
New York
|
$1.13M |
| 3 |
AWA
3
Arete Wealth Advisors
Chicago,
Illinois
|
$322K |
| 4 |
PI
4
Pennant Investors
Summit,
New Jersey
|
$248K |
| 5 |
5
BlackRock
New York
|
$4.05M |
Top Sellers
| 1 |
1
Two Sigma Investments
New York
|
$0 |
| 2 |
2
Fidelity Investments
Boston,
Massachusetts
|
$7.43M |
| 3 |
3
Vanguard Group
Malvern,
Pennsylvania
|
$3.21M |
| 4 |
4
Ameriprise
Minneapolis,
Minnesota
|
$1.6M |
| 5 |
5
Goldman Sachs
New York
|
$56.6K |
